tradingkey.logo
tradingkey.logo
Search

Hengrui Pharma Reaches Agreement with GSK, Expected to Receive $12 Billion

TigerJul 28, 2025 12:10 AM
facebooktwitterlinkedin
View all comments0

Hengrui Pharma announced that it has reached an agreement with biopharmaceutical company GSK to grant paid licenses to GSK for the global exclusive rights of the HRS-9821 project (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) and the exclusive option for the global exclusive license of up to 11 projects.

GSK will pay Hengrui $500 million as an initial payment. If all projects are granted exclusive options and all milestones are achieved, Hengrui will be eligible to receive a potential total amount of around $12 billion based on successful development, registration, and sales milestone payments.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.